Akkaraju Harshita, Tatia Ritik, Mane Sayalee Sanjay, Khade Amol B, Dengale Swapnil J
Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576 104, India.
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari, 781 101, India.
Regul Toxicol Pharmacol. 2023 Mar;139:105355. doi: 10.1016/j.yrtph.2023.105355. Epub 2023 Feb 13.
N-nitrosamines are carcinogenic impurities most commonly found in groundwater, treated water, foods, beverages and consumer products. The recent discovery of N-nitrosamines in pharmaceutical products and subsequent recalls pose a significant health risk to patients. Initial investigation by the regulatory agency identified Active Pharmaceutical Ingredients (API) as a source of contamination. However, N-nitrosamine formation during API synthesis is a consequence of numerous factors like chemistry selection for synthesis, contaminated solvents and water. Furthermore, apart from API, N-nitrosamines have also been found to embed in the final product due to degradation during formulation processing or storage through contaminated excipients and printing inks. The landscape of N-nitrosamine contamination of pharmaceutical products is very complex and needs a comprehensive compilation of sources responsible for N-nitrosamine contamination of pharmaceutical products. Therefore, this review aims to extensively compile all the reported and plausible sources of nitrosamine impurities in pharmaceutical products. The topics like risk assessment and quantitative strategies to estimate nitrosamines in pharmaceutical products are out of the scope of this review.
N-亚硝胺是最常见于地下水、处理过的水、食品、饮料和消费品中的致癌杂质。近期在药品中发现N-亚硝胺并随后召回,给患者带来了重大健康风险。监管机构的初步调查确定活性药物成分(API)是污染源。然而,API合成过程中N-亚硝胺的形成是多种因素造成的,如合成化学选择、受污染的溶剂和水。此外,除了API,由于制剂加工或储存过程中通过受污染的辅料和印刷油墨降解,N-亚硝胺也被发现存在于最终产品中。药品中N-亚硝胺污染的情况非常复杂,需要全面梳理造成药品N-亚硝胺污染的来源。因此,本综述旨在广泛梳理药品中亚硝胺杂质的所有已报道和可能的来源。本综述不涉及药品中N-亚硝胺的风险评估和定量策略等主题。